Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Isaralgagene civaparvovec

Generic Name: Isaralgagene civaparvovec

Drug Type: Biotech

CAS Number: 2378601-29-5

Unique Ingredient Identifier: 3U2455CVM6

Overview

Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme. It is developed by Sangamo Therapeutics and investigated in Fabry Disease.

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Long-Term Follow-up of Subjects Who Were Treated with ST-920

Posted: 2021/09/10

Sponsor:Sangamo Therapeutics

ID:NCT05039866

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

Phase 1

Completed

Posted: 2019/08/06

Sponsor:Sangamo Therapeutics

ID:NCT04046224

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Sangamo Therapeutics Advances Neurology Pipeline and Fabry Disease Gene Therapy Amid Financial Restructuring

2 months ago

Sangamo Therapeutics has secured FDA clearance for its first neurology IND targeting idiopathic small fiber neuropathy, with patient enrollment expected to begin in mid-2025 and preliminary efficacy data anticipated by Q4 2026.

Sangamo's Gene Therapy Shows Sustained Benefits in Fabry Disease Patients with Improved Kidney Function

4 months ago

Updated Phase 1/2 STAAR study data demonstrates sustained α-Gal A enzyme activity for up to 47 months, with all 18 ERT-dependent patients successfully discontinuing enzyme replacement therapy.

Gene Therapy Landscape Expands for Fabry Disease: Multiple Clinical Trials Show Promise in 2024

5 months ago

Multiple gene therapy trials for Fabry disease demonstrated significant progress in 2024, with AMT-191, 4D-310, and ST-920 showing promising safety and efficacy data. These therapies aim to address the underlying genetic cause of Fabry disease through different approaches, potentially offering long-term treatment options for patients.

2024 Breakthroughs and Setbacks in Lysosomal Disorder Gene Therapies

5 months ago

Major developments in lysosomal disorder treatments marked 2024, with both advances and challenges in gene therapy approaches. Notable events included Roche's discontinuation of its Pompe disease program, promising progress in Fabry disease treatment by Sangamo, and mixed results in other rare disease therapies.

GLP-1 Receptor Agonists Show Promise in Alzheimer's Disease: Key Clinical Trial Readouts Expected in 2025

6 months ago

Phase III trial results for semaglutide (EVOKE and EVOKE Plus) are anticipated in September 2025, investigating its potential to slow cognitive decline in Alzheimer's patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy